Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

BACKGROUND: Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR). Despite initial responses, pati...

Full description

Saved in:
Bibliographic Details
Published in:PLoS Med
Main Authors: Pao, William, Miller, Vincent A, Politi, Katerina A, Riely, Gregory J, Somwar, Romel, Zakowski, Maureen F, Kris, Mark G, Varmus, Harold
Format: Artigo
Language:Inglês
Published: PLOS 2005
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC549606/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15737014/
https://ncbi.nlm.nih.govhttps://doi.org/10.1371/journal.pmed.0020073
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items